[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69832173D1 - Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung - Google Patents

Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung

Info

Publication number
DE69832173D1
DE69832173D1 DE69832173T DE69832173T DE69832173D1 DE 69832173 D1 DE69832173 D1 DE 69832173D1 DE 69832173 T DE69832173 T DE 69832173T DE 69832173 T DE69832173 T DE 69832173T DE 69832173 D1 DE69832173 D1 DE 69832173D1
Authority
DE
Germany
Prior art keywords
taxanes
compositions
oral administration
oral
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69832173T
Other languages
English (en)
Other versions
DE69832173T2 (de
Inventor
Samuel Broder
L Duchin
Sami Selim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ivax Research Holdings Inc
Original Assignee
Ivax Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Research Inc filed Critical Ivax Research Inc
Application granted granted Critical
Publication of DE69832173D1 publication Critical patent/DE69832173D1/de
Publication of DE69832173T2 publication Critical patent/DE69832173T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69832173T 1997-05-27 1998-04-22 Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung Expired - Fee Related DE69832173T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27
US863513 1997-05-27
PCT/US1998/007776 WO1998053811A1 (en) 1997-05-27 1998-04-22 Method and compositions for administering taxanes orally to human patients

Publications (2)

Publication Number Publication Date
DE69832173D1 true DE69832173D1 (de) 2005-12-08
DE69832173T2 DE69832173T2 (de) 2006-08-03

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69832173T Expired - Fee Related DE69832173T2 (de) 1997-05-27 1998-04-22 Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung

Country Status (23)

Country Link
EP (1) EP0994706B1 (de)
JP (1) JP2002500667A (de)
KR (1) KR100615783B1 (de)
CN (2) CN1550231A (de)
AR (1) AR012731A1 (de)
AT (1) ATE308365T1 (de)
AU (1) AU7130098A (de)
BR (1) BR9809694A (de)
CA (1) CA2290446C (de)
CZ (1) CZ9904244A3 (de)
DE (1) DE69832173T2 (de)
DK (1) DK0994706T3 (de)
ES (1) ES2247690T3 (de)
HK (1) HK1026637A1 (de)
HU (1) HUP0003546A3 (de)
IL (2) IL132992A0 (de)
NO (1) NO995812L (de)
PL (1) PL337064A1 (de)
RU (1) RU2205005C2 (de)
SK (1) SK157599A3 (de)
UA (1) UA74767C2 (de)
WO (1) WO1998053811A1 (de)
ZA (1) ZA984268B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
EP1001769B1 (de) * 1997-06-20 2002-06-19 Baker Norton Pharmaceuticals, Inc. Lösliche prodrugs von paclitaxel
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
ATE337016T1 (de) 1999-05-17 2006-09-15 Cancer Res Ventures Ltd Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
WO2001030448A1 (en) * 1999-10-27 2001-05-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
NZ539046A (en) * 2001-01-18 2006-11-30 Pharmacia & Upjohn Co Llc Chemotherapeutic self-emulsifying microemulsion compositions of paclitaxel with improved oral bioavailability
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
SI1372636T1 (sl) * 2001-02-28 2006-12-31 Bristol Myers Squibb Co Metronomsko odmerjanje taksanov za inhibiranje tumorske rasti
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
JP2012528875A (ja) * 2009-06-02 2012-11-15 ナイカン ファーマシューティカルズ， エルエルシー 疾患の処置のためのヒトホルミルペプチド受容体の拮抗作用
CA3212816A1 (en) * 2021-03-17 2022-09-22 Dompe' Farmaceutici Spa C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4059497A1 (de) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitoren zur behandlung von hypersensitivitätsreaktionen auf taxane

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
SG45403A1 (en) * 1991-01-11 1998-01-16 Glaxo Lab Sa Acridine derivatives
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
EP0773938B1 (de) * 1994-07-26 1999-02-03 INDENA S.p.A. Semisynthetisch taxal derivate mit antitumor wirkung
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
EP0831870A4 (de) * 1995-06-07 1998-09-16 Avmax Inc Die verwendung von essentiellen ölen zur erhöhung der bioverfügbarkeit von oral applizierten pharmaka
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2221444A1 (en) * 1996-01-31 1997-08-07 Steven B. Hansel A method of making pharmaceutically active taxanes orally bioavailable
EP0814081A1 (de) * 1996-06-17 1997-12-29 Eli Lilly And Company Drogenresistente und multidrogenresistente Modulatoren
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2326485C (en) * 1998-04-01 2008-12-09 Rtp Pharma Inc. Anticancer compositions

Also Published As

Publication number Publication date
RU2205005C2 (ru) 2003-05-27
HUP0003546A3 (en) 2002-12-28
IL132992A (en) 2006-08-20
DE69832173T2 (de) 2006-08-03
HK1026637A1 (en) 2000-12-22
CN1261275A (zh) 2000-07-26
BR9809694A (pt) 2000-10-03
AU7130098A (en) 1998-12-30
EP0994706A1 (de) 2000-04-26
IL132992A0 (en) 2001-03-19
AR012731A1 (es) 2000-11-08
CN1550231A (zh) 2004-12-01
CA2290446C (en) 2008-01-29
WO1998053811A1 (en) 1998-12-03
NO995812L (no) 2000-01-25
KR20010013025A (ko) 2001-02-26
SK157599A3 (en) 2002-10-08
KR100615783B1 (ko) 2006-08-25
PL337064A1 (en) 2000-07-31
UA74767C2 (en) 2006-02-15
CA2290446A1 (en) 1998-12-03
ES2247690T3 (es) 2006-03-01
ZA984268B (en) 1999-06-23
ATE308365T1 (de) 2005-11-15
CZ9904244A3 (cs) 2001-10-17
NO995812D0 (no) 1999-11-26
JP2002500667A (ja) 2002-01-08
HUP0003546A2 (hu) 2002-11-28
EP0994706B1 (de) 2005-11-02
DK0994706T3 (da) 2006-03-06
EP0994706A4 (de) 2001-05-16

Similar Documents

Publication Publication Date Title
DE69903515D1 (de) Zusammensetzung zur herstellung von temporären zahnkronen und haltebrücken
HUP0300836A3 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
PT1039909E (pt) Metodo de producao e composicao de uma preparacao oral de itraconazole
DE69918233D1 (de) Polymilchsäure zusammensetzung und daraus hergestellter film
DE69801045D1 (de) Pharmazeutische zusammensetzung zur oralen verabreichung von einem n-piperidin-3-pyrazolcarboxamid-derivat, dessen salzen und deren solvaten
DE69835103D1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE69823804D1 (de) Azeotrope methoxyperfluorpropanzusammensetzungen und deren verwendung
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DK0833612T3 (da) Ny farmaceutisk sammensætning med bedøvende virkning
ATE268597T1 (de) Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen
ITMI942025A0 (it) Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
DE69832173D1 (de) Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung
MA26553A1 (fr) Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
ATE186447T1 (de) Zusammensetzung und verwendung
DE69729570D1 (de) Fotpempfindliche zusammensetzung und deren verwendung
EE9800234A (et) Ravimeetod ja farmatseutiline kompositsioon
DE69724629D1 (de) Zusammensetzungen und deren verwendungen
DE60120416D1 (de) Polyaminoestern und deren verwendung zur herstellung von dentalmassen
DE69522188D1 (de) Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
ATE534636T1 (de) Krystalline form ii von ritonavir enthaltende pharmazeutische zusammensetzung und ihre herstellung
DE69803867D1 (de) Reinigende kosmetische zusammensetzung und verwendung
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
DE69813287D1 (de) Lipidzusammensetzungen und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee